Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study.

ABSTRACT:

Objectives

There was initially insufficient understanding regarding suitable pharmacological treatment for pediatric Coronavirus Disease 2019 (COVID-19) patients. Lopinavir-ritonavir (LPV/r) was originally used for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infection. It was also used in patients with severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) with positive results. Nonetheless, results from recent randomized controlled trials and observational studies on COVID-19 patients were unfavorable. We sought to evaluate the clinical outcomes associated with early treatment with LPV/r for pediatric COVID-19 patients.

Study design

A total of 933 COVID-19 patients aged ≤ 18 years were admitted between 21 January 2020 and 31 January

SUBMITTER: Wong CKH 

PROVIDER: S-EPMC9012665 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature